The surprising suggestion in today’s Fierce Pharma trade newsletter is that China’s high-profile arrest of GSK executives for corruption might be linked to the country’s desire to get a better deal from companies. A part of this is probably self-evident: if companies really are spending a lot of money bribing doctors (a big “if”) then the prices of pharma products would have gone up to reflect these costs.

However James Zimmerman,  former chairman of the American Chamber of Commerce in China, seems to be going further. He told Reuters , “My take is that the PRC government is targeting the industry given that cost-effective health care for the masses is a critical current policy objective for China’s aging population,”